Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Brand-Specific Enhanced Safety Surveillance Study of GSK's Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season.
Dos Santos G, Wang H, Jindal P, Rybo M, Roul H, Pallem S, Eckermann T, Godderis L, Martínez Gómez X, Godard E, Soler M, Yousefi M, Salamanca de la Cueva I, Nwoji U. Dos Santos G, et al. Among authors: martinez gomez x. Infect Dis Ther. 2022 Feb;11(1):463-483. doi: 10.1007/s40121-021-00571-y. Epub 2021 Dec 27. Infect Dis Ther. 2022. PMID: 34961900 Free PMC article.
Brand-Specific Enhanced Safety Surveillance of GSK's Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain for the 2018/2019 Season.
Dos Santos G, Nguyen BY, Damaso S, Godderis L, Martínez-Gómez X, Eckermann T, Loos H, Salamanca de la Cueva I, Shende V, Schmidt AC, Yeakey A. Dos Santos G, et al. Among authors: martinez gomez x. Drug Saf. 2020 Mar;43(3):265-279. doi: 10.1007/s40264-019-00893-4. Drug Saf. 2020. PMID: 31884676 Free PMC article.
Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
Salamanca de la Cueva I, Cinconze E, Eckermann T, Nwoji U, Godderis L, Lu E, Martínez-Gómez X, Wang H, Yanni E. Salamanca de la Cueva I, et al. Among authors: martinez gomez x. Drug Saf. 2021 Dec;44(12):1375-1390. doi: 10.1007/s40264-021-01121-8. Epub 2021 Oct 25. Drug Saf. 2021. PMID: 34694589 Free PMC article.
Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient-reported outcome system for vaccine safety remote monitoring.
Dos Santos G, Eckermann T, Martínez-Gómez X, Parra J, Nwoji U, Salamanca de la Cueva I. Dos Santos G, et al. Among authors: martinez gomez x. Influenza Other Respir Viruses. 2023 Mar;17(3):e13098. doi: 10.1111/irv.13098. Influenza Other Respir Viruses. 2023. PMID: 36991538 Free PMC article.
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
Hardt K, Vandebosch A, Sadoff J, Le Gars M, Truyers C, Lowson D, Van Dromme I, Vingerhoets J, Kamphuis T, Scheper G, Ruiz-Guiñazú J, Faust SN, Spinner CD, Schuitemaker H, Van Hoof J, Douoguih M, Struyf F; ENSEMBLE2 study group. Hardt K, et al. Lancet Infect Dis. 2022 Dec;22(12):1703-1715. doi: 10.1016/S1473-3099(22)00506-0. Epub 2022 Sep 13. Lancet Infect Dis. 2022. PMID: 36113538 Free PMC article. Clinical Trial.
Influenza Vaccine Effectiveness against Hospitalization, Season 2021/22: A Test-Negative Design Study in Barcelona.
Fornaguera M, Parés-Badell O, Carbonés-Fargas Í, Andrés C, Rodrigo-Pendás JÁ, Borras-Bermejo B, Armadans-Gil L, Tejada G, Guananga D, Vivet-Escalé M, Peñalver-Piñol A, Torrecilla-Martínez I, Del Oso A, Martínez-Gómez X, Antón A, Otero-Romero S. Fornaguera M, et al. Among authors: martinez gomez x. Vaccines (Basel). 2023 Sep 2;11(9):1450. doi: 10.3390/vaccines11091450. Vaccines (Basel). 2023. PMID: 37766127 Free PMC article.
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial.
Borobia AM, Carcas AJ, Pérez-Olmeda M, Castaño L, Bertran MJ, García-Pérez J, Campins M, Portolés A, González-Pérez M, García Morales MT, Arana-Arri E, Aldea M, Díez-Fuertes F, Fuentes I, Ascaso A, Lora D, Imaz-Ayo N, Barón-Mira LE, Agustí A, Pérez-Ingidua C, Gómez de la Cámara A, Arribas JR, Ochando J, Alcamí J, Belda-Iniesta C, Frías J; CombiVacS Study Group. Borobia AM, et al. Lancet. 2021 Jul 10;398(10295):121-130. doi: 10.1016/S0140-6736(21)01420-3. Epub 2021 Jun 25. Lancet. 2021. PMID: 34181880 Free PMC article. Clinical Trial.
[Polymyositis-dermatomyositis: incidence in Spain (1997-2004)].
Vargas-Leguás H, Selva-O'Callaghan A, Campins-Martí M, Hermosilla Pérez E, Grau-Junyent JM, Martínez Gómez X, Vaqué Rafart J. Vargas-Leguás H, et al. Among authors: martinez gomez x. Med Clin (Barc). 2007 Nov 24;129(19):721-4. doi: 10.1157/13113285. Med Clin (Barc). 2007. PMID: 18053482 Spanish.
60 results